2013 | A Phase I/IIa study of safety, tolerability, and pharma-cokinetic profiles of TG-2349, a pan-genotypic HCV protease inhibitor, in healthy East Asian and Caucasian subjects, and its antiviral activity in chronic hepatitis C patients | Tsai, Chen-En; Chang, Li-Wen; Chang, Yu-Ting; Hsu, Chiung-Yuan; Chen, Chih-Ming; Tsai, Cheng-Yuan; Lin, Chu-Chung; King, Chi-Hsin R.; Liu, Chun-Jen; Chen, Ding-Shinn; Hsu, Ming-Chu | Hepatology | | | |
2006 | Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor | Yang, Syaulan; Chen, Shu-Jen; Hsu, Min-Feng; Wu, Jen-Dar; Tseng, Chien-Te K.; Liu, Yu-Fan; Chen, Hua-Chien; Kuo, Chun-Wei; Wu, Chi-Shen; Chang, Li-Wen; Chen, Wen-Chang; Liao, Shao-Ying; Chang, Teng-Yuan; Hung, Hsin-Hui; Shr, Hui-Lin; Liu, Cheng-Yuan; Huang, Yu-An; Chang, Ling-Yin; Hsu, Jen-Chi; Peters, Clarence J.; Wang, Andrew H.-J.; Hsu, Ming-Chu; WEN-CHANG CHEN | Journal of Medicinal Chemistry | | | |